Interim Analyses LANREL07484: Response to Treatment and Self-Reported Satisfaction in Symtoms in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa Abstract #2063

Introduction: An ongoing South African observational study in patients with symptomatic gastroenteropancreatic neuroendocrine tumours (GEP-NET)
Aim(s): To evaluate patient’s level of satisfaction and symptomatic response with diarrhoea and/or flushing when treated with Lanreotide Autogel over a six-month period. Quality of life, exposure to treatment and safety of Lanreotide Autogel in patients with GEP-NET treated with Lanreotide Autogel are also being measured
Materials and methods: This is a national, on-going, multi-centre, prospective observational cohort study involving 11 oncology sites in South Africa. The decision on treatment is made in accordance with routine clinical practice at the centre concerned. Patients are followed-up for 6 months (6M) after commencing treatment with Lanreotide Autogel. The data is collected prospectively at a baseline visit, 3 months (3M) and 6M after initiation. Response to treatment reported in this abstract is an interim analysis of the data available for 23 patients (9th June 2015 - 7th August 2017)
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Monique Nel

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result